Neoleukin Therapeutics
Seattle
About Neoleukin Therapeutics
Neoleukin Therapeutics emerged from the University of Washington Institute for Protein Design in January of 2019. They are creating next generation immunotherapies using breakthrough de novo protein design technology. They use natural protein complexes as inspiration to develop custom designed proteins with superior pharmaceutical properties.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $157.6M
- Funding stage: M&A
- Last round: Post-IPO Equity (Jul 2020)
- Ticker: nasdaq:NLTX
- Website: neoleukin.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Medical
Social Profiles
Canonical: https://fsome.com/organization/neoleukin-therapeutics-2221923 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.